GlassScriptPhysician profile
Regina B Rouse
NPI 1487938825
$7,021.44
in general payments reported to CMS, 2019-2025
21 companies · $904 in 2025
The $904 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.94 · 2023: $5,996 · 2024: $90.50 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,818 · Travel and Lodging: $1,646 · Food and Beverage: $1,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,818.00 |
| Travel and Lodging | $1,646.33 |
| Food and Beverage | $1,526.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $5,996.04 | 2023 | |
| Novo Nordisk INC | $214.29 | 2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $193.10 | 2025 | |
| Novartis Pharmaceuticals Corporation | $113.22 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.82 | 2025 | |
| Axsome Therapeutics, INC. | $33.30 | 2025 | Sunosi |
| Amgen INC. | $32.95 | 2025 | Repatha, Repatha |
| Antares Pharma, INC. | $32.20 | 2024-2025 | Xyosted |
| Fidia Pharma USA INC. | $30.94 | 2021 | |
| Medtronic, INC. | $30.30 | 2025 | Intellis Adaptivestim |
| Scpharmaceuticals INC. | $30.30 | 2025 | |
| Abbott Laboratories | $30.15 | 2025 | |
| Merck Sharp & Dohme LLC | $24.53 | 2025 | Verquvo |
| Recordati_rare_diseases_inc. | $23.08 | 2025 | Isturisa |
| Boston Scientific Corporation | $22.28 | 2024 | Wavewriter Alpha Prime 16 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $21.93 | 2025 | Clottriever Bold Catheter |
| Insulet Corporation | $21.01 | 2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.42 | 2025 | Xifaxan |
| Kiniksa Pharmaceuticals International, Plc | $17.16 | 2024 | Arcalyst |
| Otsuka America Pharmaceutical, INC. | $15.44 | 2025 | Rexulti |
| Lilly USA, LLC | $14.98 | 2024 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Rouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.